DUSP2 and nasopharyngeal carcinoma: Targeting DNTTIP1/HDAC1 using chidamide disrupts the ERK signaling pathways and decreases MMP2 expression by upregulating dual specificity phosphatase 2 (DUSP2); this inhibits the migration, invasion, and proliferation of nasopharyngeal carcinoma cells [198].